Orexo AB (publ) (LON: 0H19)

Market Cap	49.85M
Revenue (ttm)	43.82M
Net Income (ttm)	-7.75M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	n/a
Previous Close	18.77
Day's Range	n/a
52-Week Range	1.02 - 1.63
Beta	0.66
RSI	62.60
Earnings Date	Feb 6, 2025

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment ...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 116
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H19

Financial Performance

In 2023, Orexo AB's revenue was 638.80 million, an increase of 2.32% compared to the previous year's 624.30 million. Losses were -128.30 million, -27.76% less than in 2022.

Financial numbers in SEK